PTI-202

PTI-202 is another abuse-resistant opioid.

In 2005, Pain Therapeutics and King entered into a strategic alliance to develop and commercialize REMOXY and other abuse-resistant opioid painkillers. Pain Therapeutics is substantially responsible for drug formulation, clinical development and regulatory filings for REMOXY and other abuse-resistant opioid painkillers developed under this alliance. Upon regulatory approval, King will assume sole control of and worldwide responsibility to exclusively commercialize REMOXY and other abuse-resistant opioid painkillers. Pain Therapeutics retains all development and commercial rights in Australia and New Zealand.

Pain Therapeutics Announces Positive Phase I Study Results With PTI-202
Nov 29, 2006

Pain Therapeutics and King Pharmaceuticals Initiate Clinical Program of a Second Abuse-Resistant Painkiller
Aug 2, 2006